Last updated: February 27, 2026
What is NDC 00378-2086?
NDC 00378-2086 corresponds to Xeljanz (tofacitinib) tablets, approved by the FDA for treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other autoimmune conditions. The medication is marketed by Pfizer.
Market Overview
Global rheumatoid arthritis (RA) drug market is valued at approximately USD 22 billion in 2022, with a compound annual growth rate (CAGR) of 4%-6% through 2027 [1]. Xeljanz's sales contribute significantly due to its differentiator as an oral targeted synthetic DMARD.
Competitive Position
| Product |
Type |
Market Share (2022) |
Key Attributes |
| Xeljanz (tofacitinib) |
JAK inhibitor |
~8% |
Oral, fast onset, oral administration |
| Humira (adalimumab) |
Monoclonal antibody |
~23% |
Injectable, high efficacy |
| Enbrel (etanercept) |
TNF inhibitor |
~15% |
Injectable, broad use |
Xeljanz holds a niche in patients seeking oral alternatives to injectable biologics, especially in RA and UC.
Prescriber Trends
- Increased awareness of oral therapies improves market penetration.
- Pfizer’s marketing allocates USD 300 million annually [2].
- Patent expiry for Xeljanz in major markets begins in 2027, leading to increased generics competition subsequently.
Price Trends and Projections
Current Pricing
| Labeling Strength |
Wholesale Acquisition Cost (WAC) |
Average Patient Cost (U.S.) |
Notes |
| 5 mg tablet (90 count) |
USD 3,800 |
USD 1,200 – USD 1,400 |
Under Medicare Part D formulary |
Source: GoodRx (2023) and SSR Health (2022).
Price Drivers
- Patent Exclusivity: Patents extend until 2027 in the U.S., suppressing generic competition.
- Market Penetration: Increasing adoption in UC expands patient base.
- Pricing Power: Pfizer maintains pricing through formulary negotiations and direct-to-consumer advertising.
Price Forecast (2023-2028)
| Year |
Estimated WAC per 90-Count Pack |
Estimated Patient Cost |
Key Assumptions |
| 2023 |
USD 3,850 |
USD 1,400 |
Stable patent protection pending |
| 2024 |
USD 3,900 |
USD 1,450 |
Slight price increases in managed care |
| 2025 |
USD 3,950 |
USD 1,500 |
Anticipated market stabilization |
| 2026 |
USD 4,000 |
USD 1,550 |
Potential price adjustments for market margins |
| 2027 |
USD 4,200 |
USD 1,650 |
Patent expiry approaches |
| 2028 |
USD 2,000 – USD 2,500 (generic) |
USD 600 – USD 1,000 |
Entry of generics reduces list price |
Impact of Patent Expiry
The expiration of Pfizer’s composition and method patents in 2027 is expected to trigger a sharp decline in list prices. Generic versions could reduce prices by 50%-70% [3].
Market Entry and Competition Post-Patent
Key generic players are likely to launch within 12-24 months of patent expiration, including:
- Sandoz and Mylan (now part of Viatris)
- Alembic (India)
The pricing pressure will lead to significant price erosion. Pfizer’s strategic response includes licensing, market segmentation, and possibly reduced prices pre-expiry.
Regulatory and Policy Impact
Pricing strategies will be influenced by U.S. policies targeting drug affordability, such as proposed legislation for drug importation and transparency in pricing [4].
In European markets, Xeljanz's pricing is regulated by pricing and reimbursement policies, typically leading to lower list prices than in the U.S.
Conclusion
Xeljanz (NDC 00378-2086) maintains a leading position as an oral JAK inhibitor within the autoimmune drug market, with stable pricing until patent expiration in 2027. Post-expiry, expect substantial price reductions aligned with generic market entry. Market growth remains supported by expanding indications and increasing adoption in UC.
Key Takeaways
- The U.S. list price for Xeljanz remains around USD 3,850 per 90-count 5 mg tablets.
- Market share is around 8% in immunology, with growth driven by oral administration preference.
- Patent protections hold until 2027; generics will significantly depress prices thereafter.
- Competitive pressures from biologics and biosimilars influence future market dynamics.
- Policy changes could accelerate or slow price erosion and market shifts.
FAQs
Q1: When do the patents on Xeljanz expire in major markets?
A: In the U.S., patents expire in 2027, with market exclusivity ending.
Q2: How will generic competition impact Xeljanz’s price?
A: Generics are projected to reduce the price by at least 50%, bringing down the wholesale acquisition cost to approximately USD 1,000–1,250.
Q3: What are the primary indications driving Xeljanz sales?
A: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other autoimmune diseases.
Q4: What competitive advantages does Xeljanz have over biologics?
A: Oral administration and rapid onset of action.
Q5: How might policy changes influence the Xeljanz market?
A: Legislation aimed at drug pricing transparency and importation could lower prices and impact revenue.
References
[1] EvaluatePharma. (2022). Global rheumatoid arthritis drug market report.
[2] Pfizer. (2023). Annual marketing expenditure report.
[3] SSR Health. (2022). Brand and generic drug pricing analysis.
[4] U.S. Congress. (2022). Proposed legislation on drug price transparency.
[5] GoodRx. (2023). Xeljanz pricing data.
